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Abstract
Background: Chronic HIV infection is associated with increased risk of cardiovascular disease caused by
atherosclerosis. Oxidized forms of low-density lipoprotein (LDL) are present in atherosclerotic lesions and constitute
major epitopes for natural antibodies. IgM has been shown to be protective against atherosclerosis, whereas the
role of corresponding IgG is less clear. The objective of this study was to determine if HIV + individuals have
disturbed levels of IgM and IgG directed against oxidized forms of LDL as compared to HIV- individuals.
Methods: Ninety-one HIV + patients and 92 HIV- controls were included in this retrospective study. Circulating levels
of IgG and IgM directed against two forms of oxidized LDL; copper oxidized (OxLDL) and malondialdehyde
modified (MDA-LDL), total IgM and IgG, C-reactive protein (CRP), soluble CD14, and apolipoproteins A1 and B were
determined.
Results: HIV + individuals had slightly lower levels of IgM against MDA-LDL and higher levels of IgG against
MDA-LDL, OxLDL, and total IgG, than HIV- controls. Anti-MDA-LDL and Anti-OxLDL IgG displayed a positive
correlation with viral load and a negative correlation with the CD4+ T-cell count. HIV + individuals also displayed
elevated CRP and soluble CD14 levels compared to HIV- individuals, but there were no correlations between CRP or
soluble CD14 and specific antibodies.
Conclusions: HIV infection is associated with higher levels of IgG including specific IgG against oxidized forms of
LDL, and lower IgM against the same epitope. In addition to dyslipidemia, immune activation, HIV-replication and
an accumulation of risk factors for atherosclerosis, this adverse antibody profile may be of major importance for the
increased risk of cardiovascular disease in HIV + individuals.
Background
The use of antiretroviral treatment (ART) for HIV in-
fection has led to a dramatic reduction of HIV-related
morbidity and mortality, and the life expectancy of
HIV-infected individuals is now approaching that of the
general population [1-4]. As HIV-related mortality has
decreased, there has been a relative increase in the pro-
portion of deaths attributable to other complications
such as renal disease, liver disease, neurocognitive im-
pairment, and cardiovascular disease (CVD) [5]. For rea-
sons that are not yet fully understood, HIV-infected
individuals, even those on stable suppressive treatment,
have a higher prevalence of atherosclerosis than age-
matched HIV-negative adults [6-9]. This increased risk
is independent of traditional risk factors for CVD such
as high blood pressure, high cholesterol levels, and
smoking. Proposed explanations for the increased risk
include on-going HIV-replication in untreated individ-
uals, immune suppression, HIV-associated inflammation,
and the antiretroviral drugs [9-11].
HIV-infected individuals were recently reported to
have higher circulating levels of IgG directed against
copper-oxidized low-density lipoprotein (LDL) [12]. Oxi-
dized forms of LDL (OxLDL) are major constituents of
atherosclerotic plaques, the lesions causing CVD [13]. In
plaques, OxLDL is taken up by macrophages, leading to
foam cell formation. Antibodies directed against OxLDL
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may both exert pro- and anti-atherogenic effect, depend-
ing on the isotype, with IgG being mostly pro- and IgM
chiefly anti-atherogenic [14]. Animal studies have dem-
onstrated that mice lacking circulating IgM develop
more atherosclerosis than mice with normal levels of
IgM [15], and that immunization of mice with inacti-
vated Streptococcus pneumoniae, which causes increased
levels of IgM against modified LDL, is atheroprotective
[16]. One mechanism by which natural antibodies of the
IgM isotype may be protective against atherosclerosis is
by inhibiting the uptake of OxLDL into macrophages.
In humans, natural antibodies are produced by IgM +
memory-B-cells. HIV infection has been associated with
a wide range of B-cell defects, including decreased B-cell
survival [17], enhanced expression of markers of B-cell
activation, reduction of subsets of memory B-cells, poly-
clonal hypergammaglobulinemia, and impaired antibody
responses to immunizations, for example S. pneumoniae
[18-25]. Our hypothesis was that HIV-infected (HIV+)
individuals could have impaired production of natural
antibodies that are protective against atherosclerosis in
addition to their previously shown higher levels of IgG
against OxLDL [12]. We therefore set out to determine
if HIV + subjects, treatment naive or on ART, have dis-
turbed levels of IgM and IgG antibodies directed against




Chronically HIV-1 (hereafter HIV) infected individuals
were retrospectively included from the Department of
Infectious Diseases, Sahlgrenska University Hospital,
Gothenburg, Sweden between 2005 and 2010. Inclusion
criterion was available stored plasma or serum sample.
Exclusion criteria were a diagnosis of opportunistic in-
fections, tumours, or co-infections with hepatitis B and/
or C. HIV + subjects were divided into four different
groups based on their immune status and treatment
regimen. HIV + individuals who were treatment naive or
who had been off ART for more than 6 months and had
a CD4+ T-cell count < 250 × 106/L constituted the first
group. The second group was HIV + individuals who
were treatment naive or who had been off ART for more
than 6 months and had a CD4+ T-cell count > 500 ×
106/L. The other two groups consisted of HIV + indi-
viduals who had been on treatment for more than
12 months with a PI-based regimen or an NNRTI-based
regimen, respectively. Lipid-lowering treatment (prava-
statin) was used by two individuals on a PI-based regi-
men and by one individual treated with an NNRTI.
Control plasma/serum samples were obtained from healthy
HIV seronegative (HIV-) age- and gender matched blood
donors during the same time period as the samples from
the HIV+ patients were collected. For samples matched to
HIV + plasma samples, plasma was used for the analyses,
and for samples matched to HIV + serum samples, serum
was used. The following analyses were performed in all
subjects: IgG and IgM directed against OxLDL and MDA-
LDL, total IgM and IgG, highly sensitive C-reactive protein
(CRP), apolipoprotein A1 (ApoA1), apolipoprotein B
(ApoB), and soluble CD14 (sCD14). In HIV + subjects,
plasma HIV RNA, blood CD4+ T-cell counts, serum chol-
esterol, HDL-cholesterol, and triglycerides were analyzed.
The study was approved by the regional ethics committee
in Gothenburg and informed consent was obtained from
all study participants.
Measurements of antibody levels
Levels of specific IgG and IgM directed against copper
OxLDL and malondialdehyde-modified LDL (MDA-LDL)
were determined in thawed plasma/serum from all study
subjects by chemiluminescent enzyme-linked immuno-
sorbent assay (ELISA) as previously described [26]. Briefly,
microtiter plates were coated with OxLDL (5 mg/L) or
MDA-LDL (5 mg/L) and the samples were added for one
hour in dilutions of 1:200 (for IgG) or 1:100 (for IgM).
OxLDL and MDA-LDL were prepared from LDL isolated
from healthy male blood donors using the potassium
bromide ultracentrifugation method as previously de-
scribed [27,28]. Alkaline phosphatase-conjugated goat
anti-human IgM (μ-chain specific, Sigma-Aldrich, Saint
Louis, MO) and anti-human IgG (y-chain specific,
Sigma-Aldrich) were used for detection of antibodies,
and quantification was performed with Lumiphos 530
(Lumigen Inc., Southfield, MI) using LMaxII (Molecular
Devices, Sunnyvale, CA). Parallel analysis of plasma and
serum samples from 30 healthy individuals showed high
concordance between results obtained in serum versus
plasma: MDA-LDL IgG R2 = 0.96, OxLDL IgG R2 = 0.95,
MDA-LDL IgM R2 = 0.98, OxLDL IgM R2 = 0.97. Thus,
serum and plasma samples were analyzed together with-
out factorization. In order to minimize the day to day
and plate to plate variation, a calibrator (serum sample)
was added to all microtiter plates, and RLU (relative lu-
minescence unit) obtained for each sample was divided
with the RLU obtained with the calibrator. In addition,
a sample standard was included on all microtiter plates
and a maximum deviation of ±2SD from the mean re-
sult of the standard was accepted. Using this approach,
the inter- and intraassay CV for all specific antibodies
measured was < 10%.
Total IgG and IgM levels were determined in thawed
plasma/serum samples from all study subjects at the
accredited local clinical chemistry laboratory with
nephelometry using Immage 800 (Beckman Coulter,
Brea, CA).
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Other laboratory analyses
ApoA1, ApoB, and CRP were determined with immu-
nothurbidimetric methods (all from Roche Diagnostics
Scandinavia AB, Bromma, Sweden) in thawed plasma/
serum of all study individuals at the accredited local
clinical chemistry laboratory. In HIV + individuals only,
serum triglycerides, serum total-, LDL- and HDL-
cholesterol were determined with immunothurbidimetric
methods (all from Roche Diagnostics Scandinavia AB) in
fresh serum samples at the time of entry into the study
at the accredited local clinical chemistry laboratory.
Plasma HIV RNA, and blood CD4+ T-cell counts were
determined with Cobas Amplicor HIV-1 Monitor Test,
version 1.5 (Roche AB, Basel, Switzerland) and flow cy-
tometry at the accredited local clinical laboratories of vir-
ology and immunology, respectively. Circulating sCD14
levels were determined in plasma/serum samples of all
study subjects using Quantikine Human sCD14 Immuno-
assay ELISA (R&D Systems, Minneapolis, MN).
Statistical analyses
All statistical analyses were performed using SPSS Soft-
ware package 19 (SPSS Inc., Chicago, IL). Log10 trans-
formation was applied to all HIV RNA data. Data were
analyzed with Mann–Whitney U test for comparisons
between the HIV + patients and the HIV- controls, and
with Kruskal-Wallis one-way analysis of variance followed
by Dunn’s test for multiple comparisons. Relationships be-
tween continuous variables were analyzed using Spearman
correlation. P <0.05 was considered statistically significant.
Results
Clinical characteristics of the study subjects
Ninety-one HIV + subjects were included in total and di-
vided into four groups based on treatment regimen and im-
mune status; (1) treatment naive or having been off ART >
6 months with CD4+ T-cell count < 250 × 106/L (n = 22),
(2) treatment naive or having been off ART > 6 months
with CD4+ T-cell count > 500 × 106/L (n = 22), (3) treat-
ment for > 12 months with a PI-based regimen (n = 24),
and (4) treatment for > 12 months with an NNRTI-based
regimen (n = 23). The clinical characteristics of the HIV +
individuals and the HIV- controls (n = 92) are summarized
in Table 1. Treatment-naive HIV + subjects had a signifi-
cantly shorter time from diagnosis to study entrance than
HIV+ subjects on treatment, particularly subjects with
CD4+ T-cell count < 250 × 106/L. Most of these individuals
started ART shortly after being diagnosed with HIV.
Among untreated subjects, all but one was naive to ART.
The patient who previously had been treated with ART had
been without treatment for almost five years. The two
treated groups showed a comparable duration of therapy.
All treated individuals had undetectable plasma HIV RNA
levels (< 20 copies/mL).
Table 1 Demographic and treatment characteristics of study participants
Subject group
CD4 < 250 CD4 > 500 ART (PI/r) ART (NNRTI) HIV- p-value
n = 22 n = 22 n = 24 n = 23 n = 92 –
Sex (male:female) 12:10 16:6 11:13 18:5 56:36 ns
Age in years 36 (22–61) 45 (20–73) 41 (21–65) 46 (27–62) 44 (20–73) ns
Months since HIV-diagnosis 0 (0–101) 30 (3–207) 152 (32–305) 155 (50–302) – ***
CD4 nadir (× 106 cells/l) 170 (30–250) 480 (300–1000) 175 (0–310) 150 (0–470) – ***
CD4 at baseline (× 106 cells/l) 170 (40–250) 605 (520–1000) 565 (360–1100) 470 (270–900) – ***
HIV RNA (log10 copies/ml) 4.89 (2.89–5.93) 3.87 (< 1.28–5.12) All < 1.28 All < 1.28 – ***
Pre-ART HIV RNA (log10 copies/ml) – – 5.05 (2.63–6.62) 4.88 (2.92–5.79) – **
Treatment duration (months) – – 57 (28–204) 77 (28–210) – ns
Apolipoprotein B (g/L) 0.81 (0.47–1.40) 0.92 (0.47–1.40) 1.10 (0.33–1.50) 1.00 (0.47–1.80) 0.87 (0.42–2.20) *
Apolipoprotein A1 (g/L) 1.40 (0.76–2.10) 1.45 (0.94–1.90) 1.55 (1.10–1.90) 1.70 (1.10–2.80) 1.50 (1.10–2.60) ns
Total cholesterol (mmol/L) 4.2 (3.0–8.4) 5.0 (3.6–7.1) 5.7 (2.4–7.8) 6.0 (3.6–9.5) – ***
HDL-cholesterol (mmol/L) 1.3 (0.6–2.1) 1.3 (0.6–2.1) 1.2 (0.9–2.0) 1.5 (0.9–2.7) – ns
Triglycerides (mmol/L) 1.20 (0.49–4.30) 1.45 (0.50–2.50) 2.15 (0.78–9.40) 1.70 (0.71–12.00) – **
hsCRP (mg/L) 2.75 (0.17–50.00) 1.60 (0.00–12.00) 1.40 (0.00–14.00) 3.50 (0.34–11.00) 0.63 (0.0–36.00) ***
Soluble CD14 (ng/mL) 1333 (991–3762) 1491 (842–1888) 1621 (1067–2283) 1796 (1228–3528) 1259 (872–2131) ***
Significance testing was performed for all five groups where data was available for HIV- controls, otherwise only for HIV + subjects. ART: antiretroviral treament;
PI/r: ritonavir-boosted protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; hsCRP: highly sensitivity C-reactive protein. All values are given as
median (range). NS: not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
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Elevated IgG and reduced IgM levels directed against
modified LDL in HIV + subjects
HIV + subjects had significantly higher levels of IgG di-
rected against both MDA-LDL and OxLDL compared to
HIV- controls (Figure 1A–B). The highest levels of
OxLDL IgG were detected in untreated patients with
CD4+ T-cell counts < 250 × 106/L. When IgG directed
against MDA-LDL and OxLDL were normalized to total
IgG, expressed as the ratio of MDA-LDL IgG/total IgG,
the increase in OxLDL IgG persisted although there
were no significant differences in the ratio of MDA-LDL
IgG/total IgG between HIV + individuals and uninfected
controls (Figure 1C–D). Total IgG levels were signifi-
cantly higher in all HIV + individuals compared to unin-
fected controls (Figure 1E). For IgM directed against
MDA-LDL and OxLDL, the pattern differed from that
found for IgG (Figure 1F–I). HIV + patients displayed
lower levels of IgM directed against MDA-LDL, both
when MDA-LDL IgM was analyzed alone and when it
was normalized to total IgM, expressed as the ratio of
MDA-LDL IgM/total IgM (Figure 1F–G). Multiple com-
parisons showed that all HIV + subjects, except those on
treatment with an NNRTI-based regimen, had lower ra-
tios of MDA-LDL IgM/total IgM levels compared to
HIV- controls. Within the group of HIV + individuals,
total IgM levels were highest in treatment naive patients
with low CD4+ T cell counts (Figure 1J).
Correlations between antibody levels and viral load
As expected, there were strong correlations between
MDA-LDL and OxLDL IgG and MDA-LDL and OxLDL
IgM, respectively (Table 2). Somewhat unexpected, there
were strong correlations between total and MDA-LDL/
OxLDL-specific IgGs and IgMs, with a consistent
relationship between IgMs in both groups, but only in
HIV + subjects for IgG (Table 2). IgG directed against
MDA-LDL correlated with HIV RNA levels in indi-
viduals with detectable viral loads (untreated HIV + sub-
jects) (rS = 0.338, p = 0.02, n = 43). There were no
correlations between plasma HIV RNA levels and any of
the other antibodies (MDA-LDL IgM, OxLDL IgM and
IgG, and total IgM and IgG) (data not shown). OxLDL
IgG (rs = 0.236, p < 0.05), total IgG (rs = 0.284, p < 0.01),
and total IgM ((rs = 0.269, p < 0.05), but not the
remaining antibodies, correlated with the CD4+ T-cell
count in HIV + subjects.
Treatment-related differences in serum cholesterol and
triglycerides in HIV + subjects
The pattern of increased levels of IgG directed against
OxLDL and MDA-LDL and decreased levels of IgM
directed against these epitopes has previously been asso-
ciated with an increased risk of CVD. Since this associ-
ation has not been shown to be independent of other
risk factors for CVD, we assessed other markers for car-
diovascular risk in our study individuals. None of the
apolipoproteins ApoB and ApoA1 differed significantly
between HIV + and uninfected individuals. In a multiple
comparison test within the HIV + group, individuals on
treatment with an NNRTI-based regimen had higher
ApoB levels than treatment naive patients with CD4+ T-
cell count < 250 × 106/L (Figure 2 and Table 1). Serum
cholesterol, which was determined only in the HIV + in-
dividuals, also differed significantly between the different
HIV + groups (Figure 2 and Table 1). As expected, there
were positive correlations between ApoB levels and
cholesterol concentrations, as well as between ApoA1
and HDL-cholesterol (rS = 0.812 and 0.814, respectively,
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Figure 1 Concentrations of total and oxidized forms of IgM and IgG in HIV- controls and the different HIV + groups. Figure shows
HIV-negative controls (HIV-), untreated HIV + subjects with CD4 < 250 (< 250) or > 500 (> 500), and HIV + treated subjects on a boosted protease
inhibitor regimen (PI/r) or an NNRTI regimen (NNRTI). A. MDA-LDL IgG, B. OxLDL IgG, C. Ratio MDA-LDL IgG/total IgG, D. Ratio OxLDL IgG/total
IgG, E. Total IgG, F. MDA-LDL IgM, G. OxLDL IgM, H. Ratio MDA-LDL IgM/total IgM, I. Ratio OxLDL IgM/total IgM, J. Total IgM. Boxes encompass
interquartile ranges with median (line), whiskers designate the range. *p < 0.05, **p < 0.01, ***p < 0.001, a.u.: arbitrary units.
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both p < 0.001). In regard to serum triglyceride concen-
trations, patients on a PI/r based regimen had the high-
est serum triglyceride concentrations (Table 1).
Inflammation markers
One explanation for increased levels of total IgG in
HIV + individuals is a general activation of the immune
system, either due to HIV per se or due to other micro-
organisms. One such mechanism described in individ-
uals with HIV is microbial translocation, and we
therefore analyzed sCD14 in addition to the inflamma-
tion marker also proposed as a marker of cardiovascular
risk, CRP. Levels of sCD14 were higher in HIV + sub-
jects as a group compared to HIV- controls (Table 1)
Table 2 Correlations among HIV + participants
MDA-LDL IgG OxLDL IgG Total IgG MDA-LDL IgM OxLDL IgM Total IgM
MDA-LDL IgG N/A rs = 0.812 rs = 0.566 rs = 0.108 rs = 0.216 rs = 0.266
N/A p < 0.0001 p < 0.0001 p = 0.147 p = 0.003 p < 0.0001
OxLDL IgG rs = 0.812 N/A rs = 0.614 rs = 0.126 rs = 0.252 rs = 0.319
p < 0.0001 N/A p < 0.0001 p = 0.088 p = 0.001 p < 0.0001
Total IgG rs = 0.566 rs = 0.614 N/A rs = 0.038 rs = 0.120 rs = 0.391
p < 0.0001 p > 0.0001 N/A p = 0.612 p = 0.109 p < 0.0001
MDA-LDL IgM rs = 0.108 rs = 0.126 rs = 0.038 N/A rs = 0.842 rs = 0.707
p = 0.147 p = 0.088 p = 0.612 N/A p < 0.0001 p < 0.0001
OxLDL IgM rs = 0.216 rs = 0.252 rs = 0.120 rs = 0.842 N/A rs = 0.663
p = 0.003 p = 0.001 p = 0.109 p < 0.0001 N/A p < 0.0001
Total IgM rs = 0.266 rs = 0.319 rs = 0.391 rs = 0.707 rs = 0.663 N/A
p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001 N/A
hsCRP rs = 0.231 rs = 0.193 rs = 0.286 rs = 0.035 rs = 0.063 rs = 0.060
p = 0.002 p = 0.009 p < 0.0001 p = 0.63 p = 0.40 p = 0.43
Soluble CD14 rs = 0.097 rs = 0.195 rs = −0.348 rs = −0.199 rs = −0.177 rs = −0.326
p = 0.358 p = 0.064 p = 0.001 p = 0.059 p = 0.093 p = 0.002
hs: higly sensitive C-reactive protein, rs: Spearman correlation coefficient.
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Figure 2 Concentrations of apolipoproteins, total cholesterol and HDL cholesterol in the different HIV + groups. Figure shows untreated
HIV + subjects with CD4 < 250 (< 250) or > 500 (> 500), and HIV + treated subjects on a boosted protease inhibitor regimen (PI/r) or an NNRTI
regimen (NNRTI). Boxes encompass interquartile ranges with median (line), whiskers designate the range. *p < 0.05, **p < 0.01, ***p < 0.001.
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with the highest levels in patients on an NNRTI-based
regimen (Table 1). There were no correlations between
CRP or sCD14 and plasma HIV RNA levels (data not
shown). There was an inverse correlation between circu-
lating levels of sCD14 and total IgG and IgM, but no re-
lationship between sCD14 and specific IgG or IgM
directed against OxLDL or MDA-LDL (Table 2), or HIV
RNA levels (data not shown). On the other hand, there
was an inverse correlation with levels of sCD14 and
CD4+ T-cell count (rs = −0.297, p < 0.01).
Discussion
In this study, we show that chronic HIV infection is as-
sociated with elevated levels of IgG against oxidized
forms of LDL in addition to elevated levels of total IgG.
We also show that levels of these specific antibodies are
related to plasma HIV RNA levels and treatment regi-
men, but only weakly with inflammatory status.
The main objective of this study was to determine if
HIV + subjects have disturbed levels of IgG or IgM anti-
bodies against oxidized forms of LDL compared to HIV-
subjects. We found a decrease in the levels of potentially
atheroprotective IgM directed against MDA-LDL and a
major increase in the levels of IgG directed against both
MDA-LDL and OxLDL. High levels of IgGs directed
against oxidized forms of LDL, particularly in the form
of immune complexes, have previously been associated
with increased development of atherosclerosis and CVD
[29,30]. In addition, anti-OxLDL-IgG might be con-
sumed in the event of an erupted atherosclerotic plaque
as indicated by low levels of anti-OxLDL IgG in acute
coronary syndromes [31]. Low IgM levels against oxi-
dized forms of LDL and similar epitopes have consist-
ently been shown to be associated with an increased risk
of atherosclerosis [32-34]. In mice, shifting the ratio
IgG/IgM towards lower IgM and higher IgG was associ-
ated with aggravated atherosclerosis, indicating protec-
tion by IgM and harmfulness of IgG [35].
Da Cunha et al. recently reported higher IgG levels
against OxLDL in HIV-infected individuals [12]. Our
study confirms and further extends those observations.
We show that HIV + patients have higher levels of IgG
directed also against another form of modified LDL,
MDA-LDL, as well as of total IgGs. These results impli-
cate that anti-OxLDL IgG levels in HIV + individuals re-
flect a higher activity of the humoral immune system in
these individuals. Regardless of the mechanism for the in-
crease, the IgGs might play an important role for the risk
of developing atherosclerosis, especially in combination
with lower levels of IgM against modified LDL, resulting
in a possibly adverse anti-OxLDL IgG/IgM ratio.
HIV infection leads to alterations in the lipid profile
[36,37], and ART also has effects on triglyceride and chol-
esterol levels [38,39]. The incidence of dyslipidemia after
the introduction of combination ART ranges between 15
and 30%, with hypertriglyceridemia being the most com-
mon change [40]. Among the HIV + subjects, treated
patients receiving PI/r-based regimens had the highest tri-
glyceride levels. Triglyceride concentrations were not ana-
lyzed in HIV- controls. HIV + individuals on ART had the
highest levels of total cholesterol, and untreated subjects
with low CD4+ T-cell counts, the lowest levels. It has pre-
viously been shown that serum lipid levels uniformly de-
cline following HIV-seroconversion and after initiation of
ART there is a rise in total cholesterol and LDL that typic-
ally exceeds pre-infection levels, whereas the recovery of
HDL may be incomplete [36]. In HIV + individuals, the
concentration and size of LDL might be of limited value
for the risk of CVD [41]. Other potential markers of car-
diovascular risk are ApoB and ApoA1, the signature pro-
teins of LDL and HDL particles, respectively. In this
study, there were no significant differences in apolipopro-
teins between HIV + individuals and HIV- subjects. Al-
though there were correlations between levels of ApoB
and cholesterol, the differences between groups were
more pronounced for cholesterol than for ApoB.
As expected, HIV + subjects in our study had higher
hsCRP levels than HIV- controls. The reason for HIV-
associated immune activation is not fully understood, but is
likely to be multifactorial. Important factors include direct
effects of the virus and/or viral proteins, co-infections with
other pathogens, innate and adaptive immune responses
to HIV, persistent elevation of type I and II interferons, non-
antigen specific bystander activation of immune cells, dys-
regulated cytokine and chemokine production, and bacterial
products that translocate from the gut [42-44]. Immune ac-
tivation is not only present in untreated HIV + individuals,
but also in treated suppressed patients. As is the case for
hsCRP, sCD14 levels do not seem to normalize despite sev-
eral years of effective combination ART [45]. In this study,
we found higher levels of sCD14 in HIV + individuals than
in HIV- controls. There was a correlation between sCD14
and CRP, but no correlation between sCD14 and antibodies
against oxidized forms of LDL. Since there was an inverse
relationship with total IgG and IgM and no relationship be-
tween sCD14 and specific anti-OxLDL antibodies, it is un-
likely that the source of these antibodies is an increased
bacterial load reflecting for example bacterial translocation.
This study was designed to detect differences in levels
of antibodies directed against oxidation-specific epitopes.
However, the sizes of the subgroups were rather small,
resulting in limited power to detect differences in other
markers assessed in the study and to identify associa-
tions between different parameters.
Conclusions
In conclusion, HIV infection is associated with higher
levels of IgG including specific IgG against oxidized
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forms of LDL, and lower IgM against the same epitope.
In addition to dyslipidemia, immune activation, HIV-
replication and an accumulation of risk factors for ath-
erosclerosis risk factors, this adverse antibody profile
may be of major importance for the increased risk of
CVD in HIV-infected individuals.
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